EP1828192A2 — Dipeptidyl peptidase inhibitors
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2007-09-05 · 19y expired
What this patent protects
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a member selected from the group consisting of: (A), (B), (C) wherein E is CH or N, Q is selected from the group consisting of CO, CS, SO, SO2, or C=NR4, and L, X, Z…
USPTO Abstract
Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a member selected from the group consisting of: (A), (B), (C) wherein E is CH or N, Q is selected from the group consisting of CO, CS, SO, SO2, or C=NR4, and L, X, Z, R2 and R3 are as defined herein.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.